VIATRIS INC. for VIATRIS INC
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Defense DEF
S.2296 National Defense Authorization Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILL DENT | — |
| PETER WALLACE | — |
Budget/Appropriations BUD
HR 9747 Countinuing Appropriations and Extensions Act of 2025 (Title II, all provisions relating to Health Extenders)
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILL DENT | — |
| KATHARINE HAYES | — |
Health Issues HCR
S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering H.R. 1843 / S. 1302 - Increasing Transparency in Generic Drug Applications Act HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S.2658 - The Medication Affordability and Patent Integrity Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILL DENT | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
| ANNE WILSON | — |
Copyright/Patent/Trademark CPT
IP Issues related to generic medicines Patent Settlements S 1553, The PREVAIL Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILL DENT | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
| ANNE WILSON | — |
Trade (domestic/foreign) TRD
Trade issues related to generic medicines Pharmaceutical supply chain
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILL DENT | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
| ANNE WILSON | — |
Financial Institutions/Investments/Securities FIN
Policy related to corporate governance
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID MARIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.